Patents by Inventor Borge Teisner

Borge Teisner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050221392
    Abstract: The present invention relates to the use of antibodies recognizing Fetal Antigen-1 (FA1/dlk1) for the detection and isolation of cell populations in mammalian muscle. In one embodiment, myogenic progenitor cells are detected in developing, diseased or regenerating muscle. In another embodiment, muscle stem and progenitor myogenic progenitor cells are isolated from muscle tissue or from cultures containing muscle cells. The isolated cells may be used for transplantation, drug screening, production of cell type specific antibodies, and gene therapy and discovery. Transplantation of these cells may provide treatments for degenerative diseases of muscle, and for regeneration of muscle following trauma or ischemia such as myocardial infarction.
    Type: Application
    Filed: March 21, 2003
    Publication date: October 6, 2005
    Inventors: Charlotte Harken Jensen, Borge Teisner, Henrik Schroder
  • Publication number: 20040241170
    Abstract: The present invention relates to the use of antibodies recognising Fetal Antigen-1 (FA1/dlk1) for the detection and isolation of cell subpopulations from neural cell populations, in particular from cell populations from the central nervous system. In one embodiment, the dopaminergic neurons in the Substantia nigra pars compacta are detected and separated from other cell populations in this region of the brain. In another embodiment, neural stem and progenitor cells are isolated from other more committed cells in the CNS. The isolated cells may be used for transplantation, drug screening, production of cell type specific antibodies, and gene discovery.
    Type: Application
    Filed: February 23, 2004
    Publication date: December 2, 2004
    Inventors: Charlotte Harken Jensen, Borge Teisner, Mette Gronborg, Lars U Wahlberg
  • Publication number: 20010051708
    Abstract: The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion exchange chromatography and the cation exchange chromatography are preferably connected in series. An acetate buffer having a pH of about 5.0-6.0 and having a molarity of about 5-25 mM is preferably used throughout the purification process. The invention further comprises an immunoglobulin product which is obtainable by this process. The invention also relates to an immunoglobulin product which has a purity of more than 98%, has a content of IgG monomers and dimers of more than 98.5%, has a content of IgA less than 4 mg of IgA/l, and contains less than 0.5% polymers and aggregates. Said product does not comprise detergent, PEG or albumin as a stabilizer. The product is stable, virus-safe, liquid and ready for instant intravenous administration.
    Type: Application
    Filed: July 10, 2001
    Publication date: December 13, 2001
    Applicant: Statens Serum Institut
    Inventors: Inga Laursen, Borge Teisner
  • Patent number: 6040134
    Abstract: The present invention relates to a method of diagnosing preclinical insulin-dependent diabetes mellitus by determining the T cell response to a specific islet cell antigen fetal antigen 1 (FA1) or the presence of autoantibodies against FA1 in serum, a test kit for use in the method, as well as a pharmaceutical composition of FA1 and a method for use of the pharmaceutical composition for therapy of insulin-dependent diabetes mellitus.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: March 21, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Ole Dragsbaek Madsen, Birgitte Koch Michelsen, Jacob Steen Petersen, Bart O. Roep, Borge Teisner